• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    11/21/23 4:31:06 PM ET
    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • Lexaria Bioscience (NASDAQ:LEXX) stock increased by 19.0% to $1.5 during Tuesday's after-market session. The market value of their outstanding shares is at $14.6 million.
    • Personalis (NASDAQ:PSNL) stock rose 11.6% to $1.63. The company's market cap stands at $79.8 million.
    • Atreca (NASDAQ:BCEL) stock increased by 9.47% to $0.23. The company's market cap stands at $9.1 million.
    • Moleculin Biotech (NASDAQ:MBRX) shares moved upwards by 9.15% to $0.57. The company's market cap stands at $16.9 million.
    • Exagen (NASDAQ:XGN) shares increased by 6.44% to $1.65. The company's market cap stands at $27.9 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 6.06% to $1.84. The market value of their outstanding shares is at $1.0 million.

    Losers

    • Ainos (NASDAQ:AIMD) stock decreased by 11.0% to $0.57 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 612.6K shares, which is 4173.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $11.5 million.
    • Altamira Therapeutics (NASDAQ:CYTO) stock fell 8.43% to $0.34. This security traded at a volume of 3.8 million shares come close, making up 47.3% of its average volume over the last 100 days. The company's market cap stands at $2.6 million.
    • SILO Pharma (NASDAQ:SILO) stock declined by 7.07% to $1.71. At the close, SILO Pharma's trading volume reached 2.8 million shares. This is 12852.0% of its average volume over the last 100 days. The company's market cap stands at $5.3 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock declined by 6.18% to $0.31. The market value of their outstanding shares is at $13.8 million.
    • UpHealth (NYSE:UPH) shares declined by 5.28% to $0.75. The market value of their outstanding shares is at $12.8 million.
    • TRACON Pharma (NASDAQ:TCON) shares fell 5.07% to $0.21. Trading volume for this security closed at 31.0 million, accounting for 1182.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $BCEL
    $CYTO
    $EIGR

    CompanyDatePrice TargetRatingAnalyst
    Personalis Inc.
    $PSNL
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Personalis Inc.
    $PSNL
    5/15/2025$6.00Buy
    Guggenheim
    Personalis Inc.
    $PSNL
    3/17/2025$8.00Buy
    Canaccord Genuity
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    More analyst ratings

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis to Participate in the 25th Annual Needham Virtual Conference

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at

    4/1/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    China SXT Pharmaceuticals, Inc. Announces Share Re-classification

    TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting

    3/23/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

    First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient PopulationEnrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Takes Shape HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the fin

    3/23/26 8:31:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    SEC Filings

    View All

    Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    4/2/26 4:15:09 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form DEFA14A filed by Personalis Inc.

    DEFA14A - Personalis, Inc. (0001527753) (Filer)

    4/2/26 4:07:10 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Personalis Inc.

    DEF 14A - Personalis, Inc. (0001527753) (Filer)

    4/2/26 4:03:19 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bunka Christopher

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    3/18/26 11:37:13 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO AND COO Tachibana Aaron was granted 34,375 shares, increasing direct ownership by 21% to 198,833 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/17/26 4:59:16 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SVP and Chief Legal Officer Moore Stephen Michael was granted 28,125 shares, increasing direct ownership by 44% to 92,325 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/17/26 4:57:49 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Personalis with a new price target

    Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00

    12/2/25 8:29:48 AM ET
    $PSNL
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Exagen from Sector Weight to Overweight and set a new price target of $12.00

    7/30/25 7:17:58 AM ET
    $XGN
    Medical Specialities
    Health Care

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

    Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l

    3/17/26 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, March 24, 2026: U.

    2/24/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will

    2/12/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $AIMD
    $BCEL
    $CYTO
    $EIGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care